Synthon was founded in 1991. Within two years, our creative vision and passion for making healthcare more affordable led to the development of a generic version of dobutamine, a sympathomimetic drug used in the treatment of heart failure and cardiogenic shock. The success of this first product marked the start of our rapid international growth.
Synthon quickly grew from a Nijmegen-based company employing fewer than a hundred people into the fully-fledged company it is today with laboratories, offices and production plants in nine countries around the world and products currently approved by regulatory agencies in around 100 countries worldwide.
1991: Founded in the Netherlands
1993: Launched first product: generic dobutamine
1994: Opened R&D facility in Prague, CZ
1997: Opened office in North Carolina, U.S.
1998: Acquired drug product manufacturing facility in Spain
2000: Acquired API production facility in Blansko, CZ
2001: Acquired API production facility in Argentina
2003: Introduced simvastatin
2006: Introduced tamsulosin
2007: Acquired Laboratorios Rider in Chile
2007: Launched biopharmaceuticals business
2009: Opened new R&D and production unit in Blansko, CZ
2009: Opened office in Moscow, RU
2010: Acquired Laboratorios Nafar in Mexico
2010: Opened office in South Korea
2011: Opened new biopharmaceutical laboratories in Nijmegen, NL
2011: Acquired Syntarga in the Netherlands
2012: Multi-purpose GMP drug manufacturing facility in Chile in business
2012: Licensed biosimilar trastuzumab to Amgen/Watson (now: Amgen/Actavis)
2012: Inauguration of R&D pilot plant in Argentina
2013: New antibody-drug conjugation (ADC) facility operational
2014: New monoclonal antibody production (mAb) facility established in Nijmegen, NL
2014: Opened new plant dedicated to the manufacture of API in Argentina
2014: Opened new facility for linker-drug production in Blansko, CZ
2015: Successful completion of Phase III clinical trial with glatiramer acetate 20 mg/mL
2016: Approval obtained for glatiramer acetate 20 mg/mL in Europe
2016: Opened laboratory dedicated to the development of high-potent molecules in Chile
2017: Initiation of the pivotal Phase III TULIP trial®
2018: U.S. FDA Fast Track designation for [vic-]trastuzumab duocarmazine
2019: BC Partners acquires Synthon International Holding B.V.